Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 17, 2008, Pages 8109-8116

  Thomas, Mickaël ^a   Clarhaut, Jonathan ^a   Tranoy Opalinski, Isabelle ^a   Gesson, Jean Pierre ^a   Roche, Joëlle ^a   Papot, Sébastien ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

Glucuronidase; Chemotherapy; HDAC inhibitors; Prodrugs

Indexed keywords

4 N ACETYLDINALINE; 6 [2 (4 ACETYLAMINOBENZOYLAMINO)PHENYLCARBAMOYLOXY] 3,4,5 TRIHYDROXYTETRAHYDROPYRAN 2 CARBOXYLIC ACID; 6 [4 [2 (4 ACETYLAMINOBENZOYLAMINO)PHENYLCARBAMOYLOXYMETHYL] 2 NITRO PHENOXY] 3,4,5 TRIHYDROXYTETRAHYDROPYRAN 2 CARBOXYLIC ACID; GLUCURONIDE; HISTONE DEACETYLASE INHIBITOR; PRODRUG; UNCLASSIFIED DRUG; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHEMICAL REACTION; DOSE RESPONSE; DRUG ISOLATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CADHERINS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDES; HISTONE DEACETYLASES; HUMANS; HYDROLYSIS; LUNG NEOPLASMS; MOLECULAR STRUCTURE; PHENYLENEDIAMINES; PRODRUGS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 50349099688     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.07.048     Document Type: Article

References (30)

1. Biel M., Wascholowski V., and Giannis A. Angew. Chem., Int. Ed. Engl. 44 (2005) 3186-3216
2. Dokmanovic M., Clarke C., and Marks P.A. Mol. Cancer Res. 5 (2007) 981-989
3. Miller T.A., Witter D.J., and Belvedere S. J. Med. Chem. 46 (2003) 5097-5116
4. Monneret C. Eur. J. Med. Chem. 40 (2005) 1-13
5. Paris M., Porcelloni M., Binaschi M., and Fattori D. J. Med. Chem. 51 (2008) 1505-1529
6. Rasheed W.K., Johnstone R.W., and Prince H.M. Expert Opin. Invest. Drugs 16 (2007) 659-678
7. el-Beltagi H.M., Martens A.C., Lelieveld P., Haroun E.A., and Hagenbeek A. Cancer Res. 53 (1993) 3008-3014
8. LoRusso P.M., Demchik L., Foster B., Knight J., Bissery M.C., Polin L.M., Leopold III W.R., and Corbett T.H. Invest. New Drugs 14 (1996) 349-356
9. Seelig M.H., and Berger M.R. Eur. J. Cancer 32A (1996) 1968-1976
10. Pauer L.R., Olivares J., Cunningham C., Williams A., Grove W., Kraker A., Olson S., and Nemunaitis J. Cancer Invest. 22 (2004) 886-896
11. Undevia S.D., Kindler H.L., Janisch L., Olson S.C., Schilsky R.L., Vogelzang N.J., Kimmel K.A., Macek T.A., and Ratain M.J. Ann. Oncol. 15 (2004) 1705-1711
12. Nemunaitis J.J., Orr D., Eager R., Cunningham C.C., Williams A., Mennel R., Grove W., and Olson S. Cancer J. 9 (2003) 58-66
13. Thomas M., Rivault F., Tranoy-Opalinski I., Roche J., Gesson J.P., and Papot S. Bioorg. Med. Chem. Lett. 17 (2007) 983-986
14. PMT: Prodrug Mono-Therapy. Bosslet K., Straub R., Blumrich M., Czech J., Gerken M., Sperker B., Kroemer H.K., Gesson J.P., Koch M., and Monneret C. Cancer Res. 58 (1998) 1195-1201
15. ADEPT: Antibody-Directed Enzyme Prodrug Therapy. Bagshawe, K.D.; Sharma, S.K.; Begent, R.H.J. Expert Opin. Biol. Ther. 2004, 4, 1777-1789.
16. GDEPT: Gene-Directed Enzyme Prodrug Therapy. Niculescu-Duvaz, I.; Springer, C.J. Mol. Biotechnol. 2005, 30, 71-88.
17. For a review see. de Graaf M., Boven E., Scheeren H.W., Haisma H.J., and Pinedo H.M. Current Pharm. Des. 8 (2002) 1391-1403
18. Papot S., Tranoy I., Tillequin F., Florent J.C., and Gesson J.P. Curr. Med. Chem. Anticancer Agents 2 (2002) 155-185
19. Florent J.C., Dong X., Gaudel G., Mitaku S., Monneret C., Gesson J.P., Jacquesy J.C., Mondon M., Renoux B., Andrianomenjanahary S., Michel S., Koch M., Tillequin F., Gerken M., Czech J., Straub R., and Bosslet K. J. Med. Chem. 41 (1998) 3572-3581
20. Duimstra J.A., Femia F.J., and Meade T.J. J. Am. Chem. Soc. 127 (2005) 12847-12855
21. Tomino S., Paigen K., Tulsiani D.R., and Touster O. J. Biol. Chem. 250 (1975) 8503-8509
22. Leenders R.G.G., Ruytenbeek R., Damen E.W.P., and Scheeren H.W. Synthesis (1996) 1309-1312
23. David Crouch R. Tetrahedron 60 (2004) 5833-5871
24. De Mesmaeker A., Hoffmann P., and Ernst B. Tetrahedron Lett. 30 (1989) 3773-3776
25. Loudni L., Roche J., Potiron V., Clarhaut J., Bachmann C., Gesson J.P., and Tranoy-Opalinski I. Bioorg. Med. Chem. Lett. 17 (2007) 4819-4823
26. Thiery J.P. Nat. Rev. Cancer 2 (2002) 442-454
27. Thiery J.P., and Sleeman J.P. Nat. Rev. Mol. Cell Biol. 7 (2006) 131-142
28. Bremnes R.M., Veve R., Gabrielson E., Hirsch F.R., Baron A., Bemis L., Gemmill R.M., Drabkin H.A., and Franklin W.A. J. Clin. Oncol. 20 (2002) 2417-2428
29. Witta S.E., Gemmill R.M., Hirsch F.R., Coldren C.D., Hedman K., Ravdel L., Helfrich B., Dziadziuszko R., Chan D.C., Sugita M., Chan Z., Baron A., Franklin W., Drabkin H.A., Girard L., Gazdar A.F., Minna J.D., and Bunn Jr. P.A. Cancer Res. 66 (2006) 944-950
30. Ohira T., Gemmill R.M., Ferguson K., Kusy S., Roche J., Brambilla E., Zeng C., Baron A., Bemis L., Erickson P., Wilder E., Rustgi A., Kitajewski J., Gabrielson E., Bremnes R., Franklin W., and Drabkin H.A. Proc. Natl. Acad. Sci. USA 100 (2003) 10429-10434